AnaptysBio Up 10% on GSK Drug Indication Approval
August 17 2021 - 6:50PM
Dow Jones News
By Josh Beckerman
AnaptysBio Inc. shares rose 10% to $27.72 after hours as a
second approved indication for a GlaxoSmithKline PLC drug will
result in a $20 million milestone payment.
The U.S. Food and Drug Administration approved GSK's Jemperli
for the treatment of adult patients with mismatch repair deficient
recurrent or advanced solid tumors.
Jemperli was generated by AnaptysBio and subsequently developed
by Tesaro Inc., which GSK bought in early 2019.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 17, 2021 18:36 ET (22:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024
